Company Overview and News


Add RVA
to your dashboard

Headline News

REVA Medical crosses a milestone by implanting naturally dissolvable stent

2017-10-16 proactiveinvestors.com.au
REVA Medical Inc (ASX:RVA) has conducted the first implant of its bioresorbable (naturally dissolving) scaffold “Fantom” at Kantonsspital Baselland in Liestal, Switzerland.

REVA Medical Announces As Chairman Of The Board Of Directors

2017-09-20 devicespace
SAN DIEGO, Sept. 20, 2017 (GLOBE NEWSWIRE) -- REVA Medical, Inc. (ASX:RVA) (“REVA” or the “Company”) announced today that its Board of Directors has appointed Ray Larkin Jr., a current member of the Company’s Board of Directors, as Chairman of the Board, effective September 18, 2017. Mr. Larkin replaced Brian Dovey, who stepped down as Chairman, but will remain on the Company’s Board of Directors. (15-0)

Global Bioabsorbable Stents Market to Reach US$ 350 Mn by 2022 - Future Market Insights

2017-09-13 prnewswire
Bioabsorbable stents function like normal medical stents. The main difference between regular stents and bioabsorbable stents is the material which is used in their manufacturing; bioabsorbable stents use material which is easily absorbed in the body. (1-0)

REVA Medical Cuts Jobs, Shakes Up C-Suite

2017-07-14 devicespace
SAN DIEGO, July 13, 2017 (GLOBE NEWSWIRE) -- REVA Medical, Inc. (ASX:RVA), as part of its transition to commercial operations, today announced the hiring of a new chief financial officer, a vice president of European sales, and the appointment of a new director to its board. These changes signal the shift in focus to commercial roll out of Fantom, which has commenced in Europe. As part of these changes, the Company also announced the retirement of two long-serving executives and one board member.

San Diego's REVA Medical Completes $34.6 Million Funding Round

2017-06-20 devicespace
SAN DIEGO, June 19, 2017 (GLOBE NEWSWIRE) -- REVA Medical, Inc. (ASX:RVA) (“REVA” or the “Company”) announces that it has closed the second tranche and, therefore, has completed the financing transaction announced in April 2017 and approved by the Company’s shareholders on June 1, 2017. Completion occurred on June 16, 2017 with the receipt of US$13.3 million cash proceeds in exchange for the issuance of US$13.

REVA Medical Symposium Showcases Clinical Data

2017-05-18 devicespace
SAN DIEGO, May 17, 2017 (GLOBE NEWSWIRE) -- Today at the Paris Course on Revascularization (“EuroPCR”), REVA Medical, Inc. (ASX:RVA) (“REVA” or the “Company”) sponsored a symposium entitled, Fantom: performance gains and clinical data for a next generation BRS, which highlighted the recently announced clinical data from the FANTOM II trial. Information regarding the Company’s newly initiated clinical trials and plans for expansion was also presented.

REVA Medical Announces Positive 12-Month Clinical Results

2017-05-17 devicespace
SAN DIEGO, May 16, 2017 (GLOBE NEWSWIRE) -- At the Paris Course on Revascularization (“EuroPCR”) being held this week in Paris, France, REVA Medical, Inc. (ASX:RVA) (“REVA” or the “Company”) announced sustained positive clinical results from the FANTOM II clinical trial. The trial is evaluating the safety and performance of the Company’s Fantom sirolimus-eluting bioresorbable coronary scaffold in 240 patients outside the United States.

AtriCure's (ATRC) CEO Mike Carrel on Q1 2017 Results - Earnings Call Transcript

2017-05-05 seekingalpha
Good afternoon and welcome to AtriCure's First Quarter 2017 Earnings Conference Call. My name is Shannon, and I'll be your coordinator for the call today. At this time, all participants are in listen-only mode. We will be facilitating a question-and-answer session towards the end of today's call. As a reminder, this call is being recorded for replay purposes.

REVA Medical Arranges Convertible Note Financing

2017-04-25 devicespace
SAN DIEGO, April 24, 2017 (GLOBE NEWSWIRE) -- REVA Medical, Inc. (ASX:RVA) (“REVA” or the “Company”) is pleased to announce that it has entered into an agreement with several institutional and one corporate investor to provide funding for the Company’s ongoing operating and capital needs. Under the agreement, the Company will issue convertible notes, along with options for the purchase of REVA’s common stock.

Snippet Roundup: Merck Gets Tecos Knockback, Gottlieb Moves Towards FDA Hotseat

2017-04-07 seekingalpha
Welcome to your weekly roundup of EP Vantage’s snippets – short takes on smaller news items.

REVA Medical Receives CE Mark For Fantom

2017-04-04 devicespace
SAN DIEGO, April 03, 2017 (GLOBE NEWSWIRE) -- REVA Medical, Inc. (ASX:RVA) (“REVA” or the “Company”) is pleased to announce it has received CE Mark approval for its Fantom drug-eluting bioresorbable coronary scaffold, which offers multiple and substantial performance advantages over first-generation scaffolds on the market today. Fantom is REVA’s first commercial product.

Global Bio-absorbable Stents Market 2017-2021

2017-03-09 prnewswire
The bioabsorbable stents market has evolved with the advances in technology and innovative products in the medical field. Stents are being increasingly used to treat medical conditions. The vendors are focusing on developing products that are safe, easy to use, widely available, and cost-effective. Also, some companies are adopting creative strategies and developing innovative products to ensure product differentiation in the market.

Global Interventional Cardiology Market 2017-2021

2017-03-08 prnewswire
Interventional cardiology devices are primarily related to heart disease, and most of the heart diseases have some serious medical conditions, such as angina, congestive heart failure, and arrhythmias. These are often caused by partially blocked coronary arteries, which is the most common cause of death globally. Since the 1980s, balloon angioplasty has been the standard method for treating coronary artery disease.